Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions develops and supplies public health products and medical countermeasures for government agencies, healthcare providers, and community preparedness programs. Its news centers on products such as NARCAN® Nasal Spray for opioid overdose emergencies and ACAM2000® for smallpox and mpox, along with biodefense countermeasures for threats including anthrax, botulism, and Ebola.
Recurring updates also cover quarterly results, debt refinancing and balance-sheet actions, regulatory approvals, government supply activity, and manufacturing services. The company reports on bioservices agreements and facility utilization at sites such as Canton, Massachusetts, and Winnipeg, Manitoba, where it supports vaccine, biologic, and drug product manufacturing programs.
Emergent BioSolutions (NYSE: EBS) announced participation in three major investor conferences in Q1 2022. The 40th Annual J.P. Morgan Healthcare Conference is scheduled for January 10-13, with a presentation on January 10 at 8:15 am PST. Following this, the J.P. Morgan 2022 Global High Yield & Leveraged Finance Conference will occur from February 28 to March 2, with a presentation on February 28 at 2:00 pm EST. Lastly, the Cowen & Co. 42nd Annual Health Care Conference will take place March 7-9, with the presentation details to be updated. Webcasts will be accessible live and for replay on the company’s website.
Emergent BioSolutions Inc. (NYSE: EBS) has announced that the first participant has been dosed in its phase 1 study, EBS-UFV-001, which is assessing the safety, tolerability, and immunogenicity of its investigational universal influenza vaccine. The study aims to evaluate the vaccine's effectiveness against influenza A viruses and is taking place in Australia with 60 healthy adults involved. The company emphasizes its commitment to innovative R&D and public health solutions, focusing on a vaccine that could provide broad protection against varying influenza strains.
Emergent BioSolutions (NYSE: EBS) announced a stock repurchase program authorized by its Board of Directors, allowing for the buyback of up to $250 million of its common stock. This initiative, set to expire on November 11, 2022, showcases the company's confidence in its financial stability and growth prospects. As of September 30, 2021, the company held $403.8 million in cash and equivalents, with approximately 53.7 million shares outstanding. The buyback will be executed based on market conditions and is intended to enhance shareholder value.
Emergent BioSolutions reported Q3 2021 financial results with total revenues of $329 million, a 15% decrease from Q3 2020. The net loss was $32.7 million, resulting in a net loss per diluted share of $0.61. Adjusted EBITDA was ($3.3 million). The company secured a $399 million contract modification for AV7909 and initiated a pivotal Phase 3 study for its chikungunya vaccine. A multi-year agreement with Providence Therapeutics is valued at $90 million.
The forecast for 2021 is updated to $1.7 - $1.8 billion in total revenues.
Emergent BioSolutions (NYSE: EBS) will host a conference call on November 4, 2021, at 5:00 PM ET to discuss Q3 2021 financial results, recent developments, and the full-year outlook. Interested parties can join via telephone or webcast. The call will provide insights into the company's financial performance and strategic direction as it aims to enhance public health. For more details, visit the Emergent website.
Emergent BioSolutions (NYSE:EBS) announced the first participant dosed in its pivotal phase 3 study for the CHIKV VLP vaccine, targeting chikungunya disease. This single-dose vaccine candidate is the only VLP-based option in clinical testing. The study aims to enroll over 3,150 participants across 49 U.S. sites, focusing on its safety and immune response. Previous phase 2 results indicated strong immunogenicity and a favorable safety profile. Regulatory agencies have granted the vaccine several designations to expedite its development, addressing an unmet medical need.
Shuman, Glenn & Stecker is investigating potential claims against Emergent BioSolutions (EBS) related to a securities class action lawsuit. The lawsuit alleges that Emergent's executives misrepresented the company's ability to produce COVID-19 vaccines, specifically those of Johnson & Johnson and AstraZeneca, at its Baltimore facility. Following FDA inspections revealing significant operational issues and contamination incidents, Emergent's stock fell over 15% in early April 2021 and has since dropped to around $55 per share, failing to recover.
Emergent BioSolutions (NYSE:EBS) and Providence Therapeutics have established a five-year agreement valued at approximately $90 million for contract development and manufacturing services to support the development of Providence’s COVID-19 mRNA vaccine, PTX-COVID19-B.
This collaboration will enable Emergent to manufacture tens of millions of doses in 2022, with potential for hundreds of millions more. The manufacturing will utilize Emergent’s cGMP facility in Winnipeg, Canada, underscoring their commitment to addressing global public health needs.
Emergent BioSolutions has announced the start of a Phase 3 clinical trial for its COVID-19 Human Immune Globulin (COVID-HIG) to assess its efficacy and safety as a treatment for high-risk adult patients. Sponsored by NIAID, the study aims to enroll about 800 patients and examines the effects of hyperimmune globulin products on combating COVID-19 progression. The trial, named OTAC, will compare COVID-HIG infusions against a placebo, focusing on improving patient outcomes and reducing severe illness risks, particularly for immunocompromised individuals and older adults.
Emergent BioSolutions (NYSE: EBS) will attend several key investor conferences, including the IDEAS Midwest Conference (Aug 25-26) and the Wells Fargo Virtual Healthcare Conference (Sept 9-10). Key activities include pre-recorded presentations and 1-on-1 meetings. The company aims to discuss recent developments and financial guidance during these events. Emergent BioSolutions focuses on protecting public health and plans to enhance the lives of 1 billion people by 2030. For further details, visit their website.